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Local injections of β‑NGF 
accelerates endochondral fracture 
repair by promoting cartilage 
to bone conversion
Kevin O. Rivera1,2,3, Fabrizio Russo4, Ryan M. Boileau5,6, Ryan E. Tomlinson7, 
Theodore Miclau2, Ralph S. Marcucio1,2, Tejal A. Desai1,3 & Chelsea S. Bahney1,2,8*
There are currently no pharmacological approaches in fracture healing designed to therapeutically 
stimulate endochondral ossification. In this study, we test nerve growth factor (NGF) as an 
understudied therapeutic for fracture repair. We first characterized endogenous expression of Ngf and 
its receptor tropomyosin receptor kinase A (TrkA) during tibial fracture repair, finding that they peak 
during the cartilaginous phase. We then tested two injection regimens and found that local β‑NGF 
injections during the endochondral/cartilaginous phase promoted osteogenic marker expression. 
Gene expression data from β‑NGF stimulated cartilage callus explants show a promotion in markers 
associated with endochondral ossification such as Ihh, Alpl, and Sdf-1. Gene ontology enrichment 
analysis revealed the promotion of genes associated with Wnt activation, PDGF‑ and integrin‑binding. 
Subsequent histological analysis confirmed Wnt activation following local β‑NGF injections. Finally, 
we demonstrate functional improvements to bone healing following local β‑NGF injections which 
resulted in a decrease in cartilage and increase of bone volume. Moreover, the newly formed bone 
contained higher trabecular number, connective density, and bone mineral density. Collectively, 
we demonstrate β‑NGF’s ability to promote endochondral repair in a murine model and uncover 
mechanisms that will serve to further understand the molecular switches that occur during cartilage to 
bone transformation.
Worldwide, bone fractures are associated with significant disability and morbidity, while imposing substantial 
financial burden on injured  individuals1. While bone has the capacity to fully regenerate, delayed healing or 
nonunion occurs in approximately 5–10% of  cases2. However, delayed healing rates increase to almost 50% 
in patients with vascular damage or high co-morbidity burdens such as diabetes, increased age, smoking, and 
 obesity3,4. Current standard of care for malunions is surgical intervention to increase stability or promote healing 
through the application of bone grafts. There are currently no pharmacological agents approved to accelerate 
fracture healing or treat nonunions. The development of novel orthobiologics to accelerate fracture repair could 
significantly improve patient outcomes.
Bone fractures heal primarily through endochondral ossification (EO), a process by which an avascular, 
aneural cartilage intermediate transforms into vascularized and innervated bone. Endochondral fracture repair 
is a dynamic regenerative process that proceeds through four overlapping  phases5–8. First, following the frac-
ture, a hematoma forms to stop the bleeding, contain debris, and activate a pro-inflammatory response that 
initiates repair within the first 3–5 days in a murine fracture  model9,10. During this pro-inflammatory phase, 
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osteoprogenitor cells along the bone surfaces undergo direct osteogenic differentiation (intramembranous ossifi-
cation) to form new bone along the existing bone adjacent to the fracture site. Later, in the fracture gap, periosteal 
progenitor cells migrate across the fibrin matrix of the hematoma to differentiate into chondrocytes and generate 
a provisional cartilaginous matrix starting around 5 days post-fracture11,12. Chondrocytes then mature through 
hypertrophy to promote vascular invasion, mineralization, and transformation into the osteoblasts that form the 
new bone (7–21 days)13–15. The newly-formed trabecular bone continues remodeling in the subsequent weeks 
into a cortical bone indistinguishable from native bone in form and  function6,7.
While the molecular pathways that regulate chondrogenesis and hypertrophy are well  described16,17, the 
mechanisms regulating conversion of cartilage to bone are not completely understood. Initial chondrogenic dif-
ferentiation is established through expression of transforming growth factor β (TGFβ), which stabilizes the tran-
scription factor Sox9 required for cartilage  formation18. Expression of Sox9 is critical for preventing osteogenic 
specification by suppressing Runx2 and canonical Wnt  signaling19. The process of chondrocyte hypertrophy is 
pivotal in the endochondral conversion of cartilage to bone and is a process tightly regulated through a complex 
negative feedback loop between Indian hedgehog (Ihh) and parathyroid hormone related protein (PTHrP)20. Ihh 
is a key regulator of chondrocyte hypertrophy and bone  formation21,22 with expression of Ihh observed in both 
hypertrophic chondrocytes and osteoblasts at the chondro-osseous transition zone (TZ) of fracture  calluses23,24. 
Current evidence suggests that subsequent transformation of these hypertrophic chondrocytes into osteoblasts 
is regulated by the loss of Sox9 expression and activation of canonical Wnt  signaling25–29.
Despite the importance of endochondral ossification to successful fracture repair, therapeutic approaches 
to bone regeneration have traditionally focused on promoting intramembranous ossification through the 
use of bone morphogenetic proteins (BMPs), which forms bone through direct osteoblast differentiation of 
 osteochondroprogenitors30. BMP-2 is the only osteoinductive growth factor with FDA approval for treatment 
of problematic fractures with a very narrow indication window associated with surgical implantation within a 
carrier  scaffold7,31. However, clinical application of BMP-2 in fracture healing has become very limited due to 
uncertain efficacy, high cost, and a growing profile of side effects that has forced the FDA to issue a warning 
of potential serious complications associated with BMP-232. As such, there remains an unmet clinical need for 
alternative biologics that stimulate fracture healing. Importantly, we believe there is an opportunity to develop 
novel therapeutic approaches to fracture repair that builds on the molecular and cellular foundations of endo-
chondral ossification.
While it has long been understood that bone is a highly innervated organ  system33,34 the functional role of 
innervation in bone development, homeostasis and fracture repair is complex and evolving. Nerve growth factor 
(NGF) was first discovered in the early 1950s and following decades of research it is now established for a role 
in regulating differentiation, growth, survival and plasticity of cholinergic neurons in the central and peripheral 
 systems35,36. NGF exerts its trophic function primarily by binding to the high affinity tropomyosin receptor 
kinase A (TrkA). During development, the NGF-TrkA pathway is essential for load-induced bone formation in 
mice and exogenous NGF delivery was shown to stimulate angiogenesis and activate Wnt/β-catenin signaling 
to promote osteogenic lineage  progression37,38.
Recently, NGF-TrkA signaling was shown to be acutely upregulated following stress fracture, and required for 
triggering reinnervation, vascularization, and osteoblastic activity during  repair39. Stress fractures, tiny cracks 
in the bone caused by repetitive stress over time, are unique in that they heal through intramembranous ossifi-
cation, rather than through endochondral ossification described above. In this study, we aimed to understand 
endogenous signaling patterns of NGF-TrkA during endochondral ossification and test whether NGF could be 
used therapeutically to promote healing. We hypothesized that local injections of NGF, timed to endogenous 
expression patterns, would promote endochondral fracture repair. In testing our hypothesis, this study is the 
first to identify an array of molecular switches that NGF acts upon in hypertrophic cartilage. Importantly, our 
data suggest NGF acts mechanistically to promote cartilage to bone conversion thus improving fracture repair.
Results
NGF and TRKA are expressed at the chondro‑osseous transition zone during endogenous 
endochondral fracture repair. We first sought to determine the spatiotemporal parameters of endog-
enous NGF and TrkA expression during endochondral fracture repair in a murine model of long bone healing. 
Tibia fractures were created using a three-point bending device to create closed, mid-shaft fractures in the right 
tibia of adult wild type mice (Fig. 1a). As demonstrated  previously14,15, these non-stabilized fractures generate 
a robust cartilage callus, as visualized by Hall and Brunt Quadruple (HBQ)-stained sections (cartilage = blue, 
bone = red) of tibiae harvested 14 days post-fracture, (Fig. 1b). By utilizing NGF-eGFP reporter mice, we were 
able to visualize the expression domain of NGF within the chondro-osseous transition zone (TZ) of the fracture 
callus via fluorescence microscopy (Fig. 1c). TrkA expression appeared in fewer cells but could also be found 
within cells at this transition zone utilizing TrkA-LacZ reporter mice (Fig. 1d–f).
After establishing the spatial expression patterns of NGF and TrkA at the TZ using histology, we aimed to 
define the temporal expression patterns of NGF and TrkA using gene expression. Fracture calluses were isolated 
7, 10, and 14 days following fracture, mRNA isolated using TRIzol and RT-PCR used to quantify expression of 
Ngf and TrkA. Our data show similar temporal expression patterns of Ngf and TrkA with a peak 10 days post 
fracture (Fig. 1g,h).
Endochondral delivery of β‑NGF is more osteogenic than early in fracture repair. We next 
aimed to test the therapeutic efficacy of exogenous β-NGF in long bone fracture healing. When developing 
novel therapies for fracture healing the majority of drugs are given immediately after fracture by default. How-
ever, based on the endogenous spatiotemporal expression patterns of NGF-TrkA correlating with the conversion 
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of cartilage to bone, we wanted to understand if matching therapeutic delivery to the timing of this endogenous 
expression pattern would be more efficacious. Therefore, we tested two different time points of β-NGF injec-
tions: early, during the pro-inflammatory and intramembranous phase of repair (day 4–6, Fig.  2a), or later, 
during the endochondral phase of cartilage maturation (day 7–9, Fig.  2c). Local delivery was performed on 
isoflurane anesthetized animals by injecting 0.5 μg β-NGF, or basal media as a control. Early β-NGF injections, 
resulted in significantly increased relative expression of collagen 1 (Col1) (Fig. 2b). However, there were sig-
nificant decreases in osteogenic markers osteocalcin (Oc) and osteopontin (Op); and the pro-angiogenic vascular 
endothelial growth factor (Vegf) (Fig. 2b). Interestingly, later β-NGF injections, robustly stimulated expression 
of osteogenic markers Oc and Op (Fig. 2d). We observed non-significant changes in mRNA expression of Col1 
(p = 0.06) and Vegf (p = 0.06) following β-NGF injections on the endochondral regimen (Fig. 2d).
β‑NGF stimulation of fracture‑callus derived cartilage explants promotes programs associ-
ated with endochondral ossification. The endogenous spatiotemporal expression patterns of NGF-
TrkA in the TZ and enhanced osteogenic response of cartilage to β-NGF suggested to us that hypertrophic 
cartilage could be responsive to NGF. To test this, we isolated the cartilage from day 7 fracture calluses, as done 
 previously14,15. Explants were cultured to hypertrophy in vitro and treated with or without 0.5 μg/mL recom-
binant human β-NGF, the biologically active form of  NGF40, for 24 h followed by RNA-sequencing (RNAseq). 
Similar to the in vivo study we found that the osteogenic marker Oc was significantly upregulated in the cartilage 
Figure 1.  Endogenous expression of Nerve growth factor (NGF) and its receptor Tropomyosin receptor kinase 
A (TRKA) within fracture callus during endochondral repair. (a) A gross fluoroscope image of the entire tibia 
with the red frame indicating the mid diaphyseal, unstabilized bone fracture. (b) Representative image of HBQ 
stained section of tibia fracture callus 14 days post-fracture (p.f.), (n = 4). Scale bar: 1 mm (c) Fluorescence 
image NGF-eGFP with DAPI of chondro-osseous transition zone (TZ) 14 days p.f. (n = 4). Scale bar: 200 μm. (d) 
Brightfield image of X-GAL stained callus 14 days p.f. (n = 4). Arrows indicate additional areas of LACZ + cells 
within callus. Scale bar: 500 μm (e) Higher magnification image of TZ within fracture callus. (f) Higher 
magnification image of cortical bone shows no staining. (e,f) Scale bars: 200 μm (g) Relative expression  (2-ΔCT) 
normalized to Gapdh of Ngf and (h) TrkA harvested from fracture callus at 7, 10, and 14 days p.f. Error bars 
represent SEM. *p < 0.05; determined by one-way ANOVA with Tukey’s multiple comparison test.
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explant study (p = 1.88E−24, Supplemental Table 1). Additional analysis revealed a number of other significantly 
upregulated genes established to play a role in endochondral ossification, such as, Indian hedgehog (Ihh), alka-
line phosphatase (Alpl), parathyroid hormone 1 receptor (Pth1r), Wnt receptors (Lrp5, Frzd5) and angiogenic 
receptors (Pdgfrb) (Fig. 3a). Of the downregulated genes, the two of most interest were plasmacytoma variant 
translocation 1 (Pvt1) and caspase 4 (Casp4) (Fig. 3a), both known to modulate apoptosis. A complete summary 
of differentially expressed genes is provided in Supplemental Table 2.
Subsequent functional enrichment analysis using EnrichR showed multiple categories of molecular func-
tions that were associated with endochondral ossification, fracture repair, and tissue remodeling. The three 
most significantly upregulated molecular function categories were: Wnt activation (p = 0.0067), Platelet-derived 
growth factor (PDGF) binding (p = 0.0051), and integrin binding (p = 0.013) (Fig. 3b). With additional enrich-
ment analysis, we then created a heat cluster map of differentially expressed genes according to these molecular 
function categories (Fig. 3c).
To confirm our RNAseq data suggesting Wnt was the most significantly upregulated molecular function 
following β-NGF treatment of cartilage ex vivo (Fig. 3b,c), we utilized a murine Axin2-eGFP reporter model to 
compare Wnt expression in vivo in mice treated with β-NGF to those without. Tibia fractures were made in the 
Axin2-eGFP mouse as described previously and β-NGF was injected days 7–9 post-fracture (Fig. 4a). Visually, 
our control mice showed no major presence of Axin2-eGFP positive cells in the TZ (Fig. 4b,c). However, there 
was an induction of Axin2-eGFP in cells at the TZ of β-NGF treated mice (Fig. 4d,e). Quantification by Image-J 
confirmed the induction of Axin2-eGFP after β-NGF treatment compared with the lack of Axin2-eGFP presence 
in the control group (Fig. 4f).
Figure 2.  Local β-NGF injections during hypertrophic cartilage phase promotes osteogenic marker expression. 
(a) Timeline schematic of fracture and three daily injections 0.5 μg β-NGF vs control (media injected) starting 
at 4 days post-fracture. (b) Expression levels of selected osteogenic and angiogenic markers from whole-callus 
tissue harvested 24 h after final injection. (c) Timeline of fracture and three daily injections 0.5 μg β-NGF vs 
control) starting at 7 days post-fracture. (d) Expression levels of osteogenic and angiogenic markers from whole-
callus tissue harvested 24 h after final injection. All expression levels are relative to Gapdh; calculated by  2-ΔCT. 
Error bars represent SEM. *p < 0.05, **p < 0.01; determined by 2-tailed t test.
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Figure 3.  Recombinant human β-NGF (β-NGF) promotes gene expression profile for endochondral bone formation. (a) Volcano 
plot of differentially expressed genes in hypertrophic cartilage stimulated with β-NGF. Threshold set to ≥ 1 log2 fold change (equal 
to ≥ twofold change), endochondral ossification-associated markers are denoted (n = 3). (b) Upregulated molecular function categories 
generated by EnrichR (maayanlab.cloud/Enrichr/), gene ontology terms are sorted by p values with corresponding adjusted p value 
and odds ratio (c) Heatmap depicting relative expression of genes associated with Wnt activation, PDGF binding, and integrin binding. 
p < 0.05, Benjamini–Hochberg method. Panel a was generated by the R package ggplot2 (version 3.2.1)84. Panel c was generated by 
Complexheatmap (version 2.0) on Bioconductor (Bioconductor.org).
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Figure 4.  Local injections of β-NGF induce Wnt activation in the TZ and nominal increase of endothelial cell 
infiltration of cartilage callous. (a) Timeline schematic of fracture and subsequent daily injections of β-NGF. (b) 
Representative image of HBQ stained section of the chondro-osseous transition zone (TZ) from control group 
(media injections) with (c) a corresponding fluorescent DAPI-stained image of adjacent slide. (d) Image of HBQ 
stained TZ from β-NGF treated mice with corresponding (e) fluorescent DAPI stained image of an adjacent 
slide (f) Quantification of Axin2-eGFP presence within TZ of fracture callus as percentage (%) of area. Images of 
(g) HBQ stained section of cartilage tissue within fracture callus from control group and corresponding image 
(h) of Anti-CD31 Diaminobenzidine (DAB) stained section. (i) HBQ stained section from β-NGF treated group 
and corresponding (j) CD31-DAB stained section. (k) Quantification of DAB stain within cartilaginous tissue 
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Given literature evidence that NGF signaling precedes and coordinates vascularization of bone  tissue38, we 
wanted to measure if local β-NGF injections promoted the infiltration of endothelial cells into the cartilage cal-
lus. Therefore, angiogenesis was quantified using immunohistochemistry performed to the CD31 endothelial 
cell marker day 10 post-fracture in wild type mice that received the endochondral delivery of β-NGF. Vascular 
invasion to the cartilage callus is observed in both the controls (Fig. 4g,h), with slightly more intense staining in 
the β-NGF group (Fig. 4i,j). Quantification by Image-J indicates only a nominal increase in CD31-positive cells 
in cartilage tissue of β-NGF treated mice (p = 0.12) (Fig. 4k).
Local β‑NGF injections accelerates endochondral bone formation by 14 days post‑frac-
ture. We next tested functional outcomes of fracture healing with the endochondral delivery of therapeutic 
β-NGF using histomorphometric and quantitative μCT analysis on treated and control tibias 14 days post frac-
ture. Histology clearly shows the increased formation of trabecular bone (red) and decreased cartilage (blue) 
in fractures receiving β-NGF relative to control (Fig.  5a,b). Quantification of the cartilage tissue showed an 
almost 50% decrease in absolute volume (Fig.  5c) and percent composition (cartilage volume/total volume) 
within the callus of β-NGF treated mice (Fig. 5d). Conversely, quantification of trabecular bone confirmed a 
similar increase in absolute bone volume (Fig. 5e) and composition (bone volume/total volume) of the callus 
Figure 5.  Local injections of β-NGF results in less cartilage and more bone. Representative images of HBQ 
stained section of fracture callus from (a) control group and (b) β-NGF group, 14 days post fracture. Scale bar: 
500 μm. Quantification of cartilage volume in both treatment groups, shown as (c) absolute volume and as (d) 
percent composition of the total callus volume. Quantification of bone volume in both treatment groups shown 
as (e) absolute volume and (f) percent composition. Quantification of (g) whole-callus volume (h) bone marrow 
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after β-NGF treatment (Fig. 5f). Importantly, there was no difference in volume of the callus as a whole between 
controls and β-NGF treated mice (Fig. 5g). There were also no differences in volume of bone marrow (p = 0.59) 
(Fig. 5h) or fibrous tissue (p = 0.40) between groups (Fig. 5i) suggesting that the conversion of cartilage to bone 
was accelerated in the experimental group.
μCT analysis was performed in parallel to histomorphometry on control and β-NGF treated mice 14 days post 
fracture. Gross examination of μCT images provide no obvious differences between treatment groups (Figs. 6a,b). 
However, quantitative assessment of structural indices showed a stark difference in bone architecture. β-NGF 
treated mice exhibited a 35% decrease in trabecular spacing compared to the controls (Fig. 6c), with trabecular 
number (Fig. 6d) and trabecular connective density showing dramatic increases of over 40% (Fig. 6e). Bone 
mineral density measurements also significantly increased, ~ 20%, in the fracture callus of β-NGF treated mice 
(Fig. 6f). Taken together, μCT data depict highly connected and structurally superior bone architecture in β-NGF 
treated mice indicative of a later stage of endochondral repair.
Discussion
There is an unmet clinical need for novel therapeutic approaches to accelerate fracture repair as there currently 
are no pharmacologic agents approved for this indication. Bone morphogenetic protein-2 (BMP-2) is the only 
US FDA approved biologic in fracture healing with a very narrow indication window: surgical implantation into 
acute open tibial shaft fractures stabilized with an intramedullary nail and treated within 14 days of the initial 
injury. Clinical use of BMP in fracture healing has significantly decreased and is now typically reserved to the 
most problematic fractures due to the high cost, limited evidence of clinical efficacy, and risk for severe off-target 
 effects41–44. A number of new pharmacologic agents have been explored for application in fracture healing, but 
almost all have focused on promoting intramembranous bone repair by stimulating  osteogenesis7.
This study aimed to test the therapeutic efficacy of locally administered β-NGF in accelerating long bone 
fracture repair. NGF is an understudied orthobiologic for bone regeneration. In the limited number of studies 
that have utilized recombinant NGF for promoting fracture repair, NGF was administered at very high doses, 
immediately following fractures and the osteogenic potential was attributed to increased neuroactivity with 
no comprehensive structural analysis of the newly-formed  bone45,46. More recently, an elegant study utilized 
genetic models to show NGF-TrkA is required in stress fracture repair, stimulating intramembranous healing 
by promoting peripheral nerve innervation, angiogenesis, and  osteogenesis39.
Uniquely, in our study we demonstrate that β-NGF was most efficacious in promoting long bone fracture 
healing when the drug was administered during the cartilaginous phase of repair, days 7 to 9 post fracture, 
reflecting the upregulation in endogenous Ngf and TrkA gene expression that we observed. Histological data 
utilizing NGF-eGFP and TrkA-LacZ reporter mice provide the first genetic labeling of the expression pattern 
within the callus of tibia fractures. Most notably, we find NGF and TrkA are localized predominantly at the 
chondro-osseous transition zone, where cartilage undergoes hypertrophy and transforms to bone adjacent to 
the invading  vasculature6,15. Our genetic models of endogenous NGF and TrkA localization support previous 
studies observing peak expression of neurotrophins and their receptors during the hypertrophic cartilage phase 
of  repair47–49. While our mRNA expression data show a peak at day 10, possible delays in mRNA-to-protein 
synthesis were considered when harvesting samples at day 14 for histological analysis. Histological visualization 
of NGF and TrkA expression at this timepoint demonstrate a broad and robust presence in the chondro-osseus 
transition zone of tibial fracture calluses.
Based on this endogenous spatiotemporal map of NGF-TrkA expression during long bone fracture healing, 
we hypothesized that hypertrophic cartilage was responsive to NGF stimulation. We tested this ex vivo by isolat-
ing the cartilaginous portion of day 7 fracture calluses, culturing the explants to hypertrophy, and treating with 
or without β-NGF. Utilizing RNAseq, we were able to detect over 3,000 differentially expressed genes in β-NGF 
stimulated cartilage. Of the significantly upregulated genes, many clumped into molecular pathways known to 
play a role in cartilage maturation, endochondral ossification, and tissue mineralization.
Within the pathways regulating cartilage maturation, those associated with Indian hedgehog signaling (Ihh) 
were strongly stimulated. Ihh is a known regulator of chondrocyte differentiation and the expression of Ihh has 
been observed at the transition zone of fracture  calluses23,24. Within this cluster Ptch1, a receptor for Ihh, and 
Pth1r, the receptor for both parathyroid hormone (Pth) and parathyroid hormone-related peptide (Pthrp), 
were also significantly upregulated. Ptch1 and Pth/Pthrp are established transcriptional targets of  Ihh23,50. Ihh 
signaling was shown to be required for the generation of the osteoblast lineage in endochondral ossification and 
disruption of the pathway produces abnormalities in bone  development21,22. Sdf-1 expression, modulated by Pth, 
is also produced by osteoblasts and is known to influence stem cell homing, tissue repair, and tissue regeneration 
in various contexts including bone  repair51,52. Furthermore, one of the earliest reports of a chondrocyte-derived 
cell associated with trabecular bone was identified by conditional ablation of Ihh signaling in  chondrocytes53, 
emphasizing the importance of highly coordinated chondrocyte maturation to effective endochondral ossifica-
tion. In this study we also found that β-NGF stimulated the expression of alkaline phosphatase (Alpl) which is 
associated with chondrocyte hypertrophy and essential for cartilage mineralization and endochondral bone 
 formation54,55. Alpl is among the first functional genes expressed during tissue calcification and is a commonly 
screened marker of osteoblast  differentiation56,57.
The osteogenic transformation of chondrocytes into osteoblasts during bone development and fracture repair 
is associated with the upregulation of traditional programs regulating osteogenesis and mineralization. In fact, 
we found that the canonical osteogenic marker osteocalcin was strongly upregulated by β-NGF when delivered 
both in vivo to the fracture site or to the cartilage callus explant. Through gene ontology enrichment analysis, 
we identified several molecular functions associated with osteogenesis were upregulated, with Wnt activation 
as the most significantly upregulated following β-NGF treatment. Importantly, we have recently shown that 
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Figure 6.  Local injections of β-NGF results in highly connected trabecular bone. μCT images of tibias from (a) 
control and (b) β-NGF treated mice, 14 days post fracture. Scale bar = 1 mm. Quantification of (c) trabecular 
spacing (d) trabecular number (e) trabecular connective density and (f) bone mineral density. Error bars 
represent SEM. *p < 0.05; **p < 0.01 determined by 2-tailed t test.
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Wnt/β-catenin signaling regulates cell fate decisions in hypertrophic chondrocytes at the transition zone and that 
Wnt signaling within the cartilage is required for endochondral fracture  repair27. This corroborates numerous 
published reports on the requisite of Wnt signaling in endochondral bone formation during development, and 
specifically for chondrocyte-derived  osteoblastogenesis25,28,29. NGF signaling has also been shown to modulate 
Wnt activation in several non-skeletal cell  types58,59. However, this is the first study in which this relationship 
has been noted in cartilage after in vitro stimulation with β-NGF. We further confirmed Wnt activation in vivo 
by histological analysis using Axin2-eGFP mice following local c injections. Taken together these data suggests 
β-NGF treatment stimulates Wnt-mediated cartilage to bone conversion during endochondral fracture repair. 
Additional studies are needed to determine whether Wnt activation by NGF is direct or indirect, and if it is Wnt 
ligand dependent or  independent58.
Additional gene ontology enrichment analysis resulted in PDGF binding as one of the most upregulated 
molecular function. In chondrocytes, PDGF stimulates proliferation but prevents endochondral maturation 
however, PDGF expression has principally been seen in osteoblasts during normal fracture  repair60,61. Integrin 
binding activity was also observed to be upregulated in cartilage explants stimulated with β-NGF. Integrin 
interactions in chondrocytes are known to regulate chondrocyte proliferation and apoptosis however, integrin 
signaling events in osteoblasts regulate mineralization and has been a therapeutic target for bone  regeneration62,63. 
Although we were able to determine that integrin binding as a molecular function was promoted in cartilage 
explants following β-NGF stimulation, we were unable to determine specific integrin subunits that were engaged. 
Future work consisting of blocking specific integrin subunits could prove useful in determining NGF-mediated 
activation of specific integrin subunits.
Of the downregulated genes Pvt1 and Casp4 drew our attention given that Pvt1 is known to modulate apop-
tosis and Casp4 is strongly implicated in an inflammatory form of  apoptosis64,65. Historically, hypertrophic 
chondrocytes were considered terminally differentiated and believed to undergo apoptosis during endochondral 
bone formation. However, our group and others have demonstrated that chondrocytes re-enter the cell cycle 
and through lineage tracing show that chondrocytes survive and give rise to osteoblasts in the growth plate and 
bone  regenerate14,15,20,22,66,67. Therefore, NGF-TrkA signaling in the fracture callus may play a role in promoting 
cell survival in the hypertrophic chondrocytes.
Our previous studies suggest that mineralization of the cartilage anlage and transformation of chondrocytes to 
osteoblasts during endochondral fracture healing is mediated by the invading  vasculature17,18. Interestingly, NGF 
was found to be critical to promoting angiogenesis and tissue mineralization during long bone  development38,45. 
Our RT-qPCR data of whole callus tissue show a decrease of VEGF following the earlier β-NGF injections versus 
no change in VEGF expression following the later regimen of β-NGF. However, when we measured changes to 
vascularization in β-NGF treated fractures, we did see an increase in endothelial cell presence within the carti-
lage callus, albeit nominal. The progression of fracture healing from the inflammatory phase to the cartilaginous 
phase involves many different cell types that are sensitive to a huge array of paracrine and autocrine  factors6–12. 
Because NGF’s receptor is expressed in many cell types and the heterogenous composition of the fracture cal-
lus, it’s difficult to directly correlate VEGF expression and endothelial cell presence. Nonetheless, like fracture 
healing, angiogenesis is a highly complex process and there remains a number of angiogenic factors that could 
be measured for in future  studies68. What we found most compelling is that β-NGF stimulation of cartilage 
explants significantly promoted endochondral ossification-associated pathways in the absence of a vasculature.
Given the molecular pathways modulated by β-NGF stimulation of cartilage explants, it is not surprising 
that timing of injections proved to be important in dictating the best therapeutic window of β-NGF. We found 
a stronger osteogenic effect of β-NGF when delivered during the endochondral phase of repair, as opposed 
to early, during the pro-inflammatory response and intramembranous healing. With endochondral delivery 
β-NGF, histomorphometric analyses of callus tissue resulted in a reduction in cartilage and increase in bone 
tissue compared to control. Furthermore, we did not see a change in the total volume of the fracture callus, 
therefore these data support the hypothesis that β-NGF accelerates cartilage to bone conversion. In addition 
to histomorphometry, μCT data further illustrates the high connectivity and high mineral density of the newly 
formed trabeculated bone.
Coincidentally, an increase in NGF and TrkA expression has also been observed in osteoarthritic  cartilage69. 
This is an important observation considering many processes observed in osteoarthritis occur in endochondral 
ossification, such as, cartilage tissue vascularization, innervation, and cartilage matrix  degradation70,71. The 
molecular pathways underlying these processes mirror those seen in our data, most notably the upregulation of 
Ihh, Alpl, Ptch1, and Pth1r72,73 with a recent study reporting on NGF-mediated upregulation of Ihh signaling and 
cartilage calcification of articular  chondrocytes74. Wnt and NGF signaling have been major therapeutic targets to 
inhibit the progression and pain associated with  osteoarthritis72,75,76. Our group has previously exploited these 
parallels by engineering osteoarthritic cartilage to promote endochondral bone  repair77.
Discovering and validating novel therapeutic targets that stimulate bone regeneration has the potential to 
significantly improve clinical outcomes in fracture healing. Gene expression analysis, histomorphometry and 
μCT data collectively demonstrate that β-NGF treatment during the endochondral phase of fracture repair 
stimulates osteogenesis to produce more bone tissue and that the newly formed bone is more connected and of 
higher architectural quality. A possible limitation on NGF’s clinical translation lies in its hyperalgesic effects. 
Yet, diverging from previous studies that administered NGF for 7  days45,46, our study was able to narrow NGF’s 
therapeutic window to 3 days, during the endochondral phase of repair, thus limiting the subjects’ exposure 
to exogenous NGF and ensuing hyperalgesia. Exogenous NGF’s hyperalgesic effects seems to peak within an 
hour of administration therefore, this could be further studied by simple co-injection of an analgesic such as 
 lidocaine78. Very little work has been done on relevant cell types to optimize the therapeutic dosing of NGF while 
minimizing hyperalgesia. Preclinical studies in murine models have utilized up to 20 μg of exogenous NGF per 
day yet, in vivo work has demonstrated that hyperalgesia in mice can be experienced with daily injections of 100 
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 ng79,80. Balancing the trophic benefit of NGF therapy and minimizing hyperalgesia in this context will prove to 
be another key area of research in the future.
Nevertheless, this study lays the foundation for utilizing recombinant β-NGF in endochondral fracture 
repair by providing comprehensive tissue analysis of tibial fracture calluses after therapeutic administration. 
Importantly, we add new mechanistic data that increases our understanding of the processes that regulate and 
promote cartilage to bone conversion during endochondral fracture repair, opening new avenues of mechanistic 
exploration.
Materials and methods
Study approval. Tibia fracture model. Approval was obtained from the University of California, San Fran-
cisco (UCSF) Institutional Animal Care and Use Committee (IACUC) prior to performing the mouse studies, the 
methods were carried out in accordance with relevant guidelines and regulations. Briefly, adult (10–16 weeks) 
male mice were anesthetized via inhalant isoflurane, and closed non-stable fractures were made mid-diaphysis 
of the tibia via three-point bending fracture  device14. Fractures were not stabilized as this method promotes 
robust endochondral repair. After fractures are created, animals were provided with post-operative analgesics 
(buprenorphine sustained-release). Animals were socially housed and allowed to ambulate freely.
Mice. Studies involving wildtype mice were conducted on the C57BL/6J strain obtained from Jackson Labs 
(Stock #000664). NGF-eGFP, which express eGFP under the control of the mouse NGF promoter, were gener-
ously donated by the Dr. Ryan Tomlinson at Thomas Jefferson  University81. TrkA-LacZ mice, which have a 
LacZ sequence inserted immediately following the ATG in exon 1 of the mouse Ntrk1 gene, were also kindly 
provided by Dr. Tomlinson and are commercially available from Jackson Labs (Stock #004837)82. Axin2-eGFP 
mice, which express eGFP under the Axin2 promoter/intron 1 sequences, were generously donated by the Dr. 
Jeremy Reiter at  UCSF83.
β‑NGF and control injections. Two time points were initially tested to compare osteogenic marker 
expression within fracture calluses. Injections were administered once daily for 3 days beginning either four 
days or seven days post-fracture, (Fig. 2c,d). Experimental groups consisted of 0.5 μg of recombinant human 
β-NGF in 20 μL of basal media versus control injections of basal media-only (DMEM basal media, Gibco cat 
#A1443001) using a Hamilton syringe guided by fluoroscopy. A dosage of 0.5 μg/day was derived from earlier 
protocols wherein our dose lies between the 0.1–1.4 μg/day previously  used46,79.
mRNA isolation and RT‑qPCR. After β-NGF administration, calluses were harvested 24 h following the 
final injection. After callus dissections, tissue samples were homogenized in Trizol then mRNA was extracted 
from tissue lysates by use of RNeasy Mini Kit following the manufacturer’s instructions (Qiagen cat# 74104). 
cDNA was reverse transcribed with Superscript III (Invitrogen cat# 18080), and RT-qPCR was performed using 
SYBR Green and primers as listed (Table 1). Relative gene expression was calculated by normalizing to Gapdh 
and are shown as  2-ΔCT(Fig. 2c,d).
Histology. Fractured tibiae were fixed in 4% paraformaldehyde (PFA) then decalcified in 19% ethylenedi-
aminetetraacetic acid (EDTA) for 14 days. Mice were processed for paraffin histology through a graded ethanol 
series and cleared in xylene prior to embedding in paraffin tissue blocks. Serial sections were cut at 8–10 μm 
for histological analysis. Every 10th slide was stained with standard histological protocols for Hall and Brunt’s 
Quadruple staining (HBQ) to visualize bone (red) and cartilage (blue) were used. Tissues from NGF-eGFP and 
Axin2-eGFP reporter strains were embedded in OCT and sectioned using a cryostat. Axin2-eGFP fluorescence 
was amplified by utilizing antibody conjugated to AlexaFluor488 (see section on IHC protocol). X-Gal staining 
was performed following an adapted protocol from previous  work37: samples were fixed in 4% PFA and after 
washing in PBS, samples were incubated in fresh X-Gal staining solution for 36 h at 32 °C. After PBS washes, 
samples were post-fixed in 4% PFA at 4 °C for 16–24 h, decalcified, and embedded in OCT for cryosectioning 
and staining as previously  described37.
Table 1.  Primer list.
Primer sequences
Forward (5′ to 3′) Reverse (3′ to 5′)
Gapdh TGA TGA CAT CAA GAA GGT GGT GAA G CCT TGG AGG CCA TGT AGG CCAT 
Ngf ACA GTG TAT TCA GAC AGT ACT TTT TTG AGA GAG TTC CAG TGT TTG GAG TCGAT 
TrkA AGA GTG GCC TCC GCT TTG T CGC ATT GGA GGA CAG ATT CA
Col1 CCC AGA ACA TCA CCT ATC AC TTG GTC ACG TTC AGT TGG TC
Oc CGC TCT GTC TCT CTG ACC TC TCA CAA GCA GGG TTA AGC TC
Op GCA CTC CAA CTG CCC AAG A TTT TGG AGC CCT GCT TTC TG
Vegf CTG TGC AGG CTG CTG TAA CG GTT CCC GAA ACC CTG AGG AG
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In vitro cartilage explant culture. A method previously described that reliably yields tissue that is highly 
cartilaginous, with no evidence of bone of stem cell markers was  employed14,15. Cartilage explants were isolated 
from the central portion of the day 7 fracture callus using a dissecting microscope to remove any adherent non-
cartilaginous tissues. Explants were minced, pooled, then separated randomly into treatment groups. Explants 
were grown in vitro for one week in serum-free hypertrophic chondrogenic medium [high glucose DMEM, 1% 
penicillin–streptomycin, 1% ITS + Premix (BD Biosciences Cat #354352), 1 mM sodium pyruvate, 100 ng/ml 
ascorbate-2- phosphate and  10−7  M dexamethasone] to promote hypertrophic  maturation14,15. Hypertrophic 
cartilage explants were then stimulated with or without 200 ng/mL recombinant human β-NGF (Peprotech cat# 
450-01) for 24 h, collected in TRIzol, then mRNA was extracted using RNeasy Mini Kit following the manufac-
turer’s instructions (Qiagen cat# 74104).
RNA sequencing and analysis. After mRNA extraction from hypertrophic cartilage, samples were then 
further purified by sodium acetate and isopropanol precipitation. 200  ng RNA input from each sample was 
used with Quantseq 3′ mRNA-seq Library Prep Kit FWD (Lexogen, SKU:015.24). Approximately 20 million 
single-end 50 bp reads were generated for each library on a HiSeq 4000. Reads were first trimmed for adapters 
with Cutadapt version 2.5 and then mapped to the mouse mm10 genome using STAR version 2.5.3a. Following 
alignment, reads were counted using featureCount version 1.6.4. We then performed differential gene expression 
analysis using the DESeq2 package version 1.24 and R version 3.6.1. Significantly upregulated or downregulated 
genes (P < 0.05, Benjamini–Hochberg corrected) upon treatment were entered into Enrichr (https ://amp.pharm 
.mssm.edu/Enric hr/) for gene ontology classification. Differentially expressed genes and genes of interest were 
visualized using a combination of R, ggplot2 version 3.2.1, EnhancedVolcano, and Complexheatmap version 
2.084.
Immunohistochemistry (IHC). β-NGF or control injections were administered once daily for 3  days 
beginning 7 days post-fracture into Axin2-eGFP mice. Fractured tibias were harvested 24 h after the final injec-
tion (10 days post-fracture), fixed in 4% paraformaldehyde (PFA) and decalcified in 19% ethylenediaminetet-
raacetic acid (EDTA) for 5  days. Samples were OCT-embedded then cryosections were made at a width of 
8–10 μm. Cryosections were carefully rinsed in PBS and blocked with 5% bone serum albumin for an hour. 
Primary antibodies were applied to sections overnight. Full antibody information is given below (Table  2). 
Species-specific secondary antibodies were detected using the VectaStain ABC Kit (Vector, PK-4000) and 3,3′- 
diaminobenzidine (DAB) colorimetric reaction was used to visualize CD31 + cells. Because of (d2)eGFP’s rapid 
degradation, Axin2-eGFP fluorescence was stabilized by using species-specific Alexa-Fluor-488 conjugated sec-
ondary antibody (Table 2).
Histomorphometry. β-NGF and control injections were administered once daily for 3  days beginning 
7 days post-fracture. Tibias were harvested 14 days post-fracture, fixed in 4% PFA and decalcified in 19% EDTA 
for 5 days. Mice were processed for paraffin histology, serial sections were cut at 8–10 μm for histomorphometric 
analysis using stereological  principles15. Quantification of callus composition (cartilage, bone, fibrous, marrow 
space) was determined using an Olympus CAST system (Center Valley, PA) and software by Visiopharm (Hør-
sholm, Denmark). For quantification of the tissues, 10 μm serial sections (three per slide) were taken through the 
entire leg. Tissue was stained with HBQ as described above, and the first section from every 10th slide analyzed 
such that sections were 300 μm apart. Volume of specific tissue types was determined in reference to the entire 
fracture callus by summing the individual compositions relative to the whole as previously  described15.
micro‑computed tomography (μCT). μCT analysis was performed as previously  described15,85. Fracture 
tibias were dissected free of attached muscle 14 days post-fracture, fixed in 4% PFA and stored in 70% ethanol. 
Fracture calluses were analyzed using the Scanco μCT50 scanner (Scanco Medical AG, Basserdorf, Switzer-
land) with 10 μm voxel size and X-ray energies of 55 kVp and 109 μA. A lower excluding threshold of 400 mg 
hydroxyapatite (HA)/mm3 was applied to segment total mineralized bone matrix from soft tissue in studies of 
control and β-NGF treated mice. Linear attenuation was calibrated using a Scanco hydroxyapatite phantom. The 
regions of interest (ROI) included the entire callus without existing cortical clearly distinguished by its anatomi-
cal location and much higher mineral density. μCT reconstruction and quantitative analyses were performed 
to obtain the following structural parameters: trabecular spacing (mm), trabecular number (#/mm), trabecular 
connective density as trabecular bifurcations (#/mm3), bone mineral density (mg HA/cm3), bone volume (as %), 
trabecular thickness (mm), and tissue mineral density (mg HA/cm3).
Table 2.  Antibody database.
Antibody reference
Host and target Resource identification
Rat anti-mouse CD31 BD Biosciences Cat# 553370, RRID: AB_394816
Goat anti-rat Ig (biotinylated) BD Biosciences Cat# 559286, RRID: AB_397214
Rabbit anti-GFP Cell Sig Tech Cat# 2555, RRID:AB_10692764
Goat anti-rabbit IgG Thermo Sci Cat# R-37116, RRID: AB_2556544
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Statistical analysis. Individual dots on graphs represent biological replicates, error bars represent standard 
error of the mean (SEM). Measurements were taken from distinct samples. All in vivo data were analyzed using 
GraphPad Prism (version 8, GraphPad Software, San Diego, CA). For RNAseq data please see section on RNAse-
quencing and analysis. Statistical tests used to compare between groups are specified in the corresponding figure 
legends, significant differences were defined at p < 0.05.
Data availability
All data needed to evaluate the conclusions are present in the paper and/or Supplementary Materials. Additional 
information related to this paper may be requested from the authors. RNA-seq data has been deposited into 
NCBI’s Gene Expression Omnibus (GEO) under accession code GSE150092.
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